CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin
A biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM. CNS’ lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to cross the blood-brain barrier. It is in development for the treatment of a number of serious brain and CNS oncology indications. The Company intends to enroll approximately 210 subjects across 35 clinical sites in the U.S. and also plans to expand the trial into western Europe.